Literature DB >> 24210699

The absence of Ku but not defects in classical non-homologous end-joining is required to trigger PARP1-dependent end-joining.

Wael Y Mansour1, K Borgmann, C Petersen, Ekkehard Dikomey, Jochen Dahm-Daphi.   

Abstract

Classical-non-homologous end-joining (C-NHEJ) is considered the main pathway for repairing DNA double strand breaks (DSB) in mammalian cells. When C-NHEJ is defective, cells may switch DSB repair to an alternative-end-joining, which depends on PARP1 and is more erroneous. This PARP1-EJ is suggested to be active especially in tumor cells contributing to their genomic instability. Here, we define conditions under which cells would switch the repair to PARP1-EJ. Using the end jining repair substrate pEJ, we revealed that PARP1-EJ is solely used when Ku is deficient but not when either DNA-PKcs or Xrcc4 is lacking. In the latter case, DSB repair, however, could be shuttled to PARP1-EJ after additional Ku80 down-regulation, which partly rescued the DSB repair in these mutants. We demonstrate here that PARP-EJ may work on DSB ends at high fidelity manner, as evident from the unchanged efficiency upon blocking end resection by either roscovitin or mirin. Furthermore, we demonstrate for that PARP-EJ is likewise involved in the repair of multiple DSBs (I-PpoI- and IR-induced). Importantly, we identified a chromatin signature associated with the switch to PARP1-EJ which is characterized by a strong enrichment of both PARP1 and LigIII at damaged chromatin. Together, these data indicate that Ku is the main regulator for the hierarchal organization between C-NHEJ and PARP1-EJ.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Alternative end-joining; DSB repair; Non-homologous end-joining; PARP1-dependent end-joining

Mesh:

Substances:

Year:  2013        PMID: 24210699     DOI: 10.1016/j.dnarep.2013.10.005

Source DB:  PubMed          Journal:  DNA Repair (Amst)        ISSN: 1568-7856


  21 in total

1.  Inhibition of PARP1-dependent end-joining contributes to Olaparib-mediated radiosensitization in tumor cells.

Authors:  Annika Kötter; Kerstin Cornils; Kerstin Borgmann; Jochen Dahm-Daphi; Cordula Petersen; Ekkehard Dikomey; Wael Y Mansour
Journal:  Mol Oncol       Date:  2014-07-01       Impact factor: 6.603

2.  Loss of CHD1 causes DNA repair defects and enhances prostate cancer therapeutic responsiveness.

Authors:  Vijayalakshmi Kari; Wael Yassin Mansour; Sanjay Kumar Raul; Simon J Baumgart; Andreas Mund; Marian Grade; Hüseyin Sirma; Ronald Simon; Hans Will; Matthias Dobbelstein; Ekkehard Dikomey; Steven A Johnsen
Journal:  EMBO Rep       Date:  2016-09-05       Impact factor: 8.807

Review 3.  Microhomology-Mediated End Joining: A Back-up Survival Mechanism or Dedicated Pathway?

Authors:  Agnel Sfeir; Lorraine S Symington
Journal:  Trends Biochem Sci       Date:  2015-10-01       Impact factor: 13.807

4.  Targeting of β1 integrins impairs DNA repair for radiosensitization of head and neck cancer cells.

Authors:  E Dickreuter; I Eke; M Krause; K Borgmann; M A van Vugt; N Cordes
Journal:  Oncogene       Date:  2015-06-15       Impact factor: 9.867

Review 5.  New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.

Authors:  Arijit Dutta; Chunying Yang; Shiladitya Sengupta; Sankar Mitra; Muralidhar L Hegde
Journal:  Cell Mol Life Sci       Date:  2015-01-10       Impact factor: 9.261

Review 6.  Regulation of Single-Strand Annealing and its Role in Genome Maintenance.

Authors:  Ragini Bhargava; David O Onyango; Jeremy M Stark
Journal:  Trends Genet       Date:  2016-07-19       Impact factor: 11.639

Review 7.  DNA polymerase θ (POLQ), double-strand break repair, and cancer.

Authors:  Richard D Wood; Sylvie Doublié
Journal:  DNA Repair (Amst)       Date:  2016-05-14

8.  Ku70 suppresses alternative end joining in G1-arrested progenitor B cells.

Authors:  Zhuoyi Liang; Vipul Kumar; Marie Le Bouteiller; Jeffrey Zurita; Josefin Kenrick; Sherry G Lin; Jiangman Lou; Jianqiao Hu; Adam Yongxin Ye; Cristian Boboila; Frederick W Alt; Richard L Frock
Journal:  Proc Natl Acad Sci U S A       Date:  2021-05-25       Impact factor: 11.205

9.  A Novobiocin Derivative, XN4, Inhibits the Proliferation of Chronic Myeloid Leukemia Cells by Inducing Oxidative DNA Damage.

Authors:  Lixian Wu; Xianling Chen; Lisen Huang; Jue Tian; Fang Ke; Jianhua Xu; Yuanzhong Chen; Ming Zheng
Journal:  PLoS One       Date:  2015-04-30       Impact factor: 3.240

Review 10.  Development of synthetic lethality anticancer therapeutics.

Authors:  Bingliang Fang
Journal:  J Med Chem       Date:  2014-06-13       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.